# Phase 2 Diabetes Mellitus, Type 1 trials: 40 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 40 trials in phase 2 for Diabetes Mellitus, Type 1 that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Diabetes Mellitus, Type 1 trials: 40 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/diabetes-mellitus-type-1

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 40
- Recruiting or not yet: 40
- Read on: November 19, 2026

## Trials

The 25 newest of 40, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07889505 | A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes | Pharmasaga Co. Ltd. | Phase 2 | Not yet recruiting | Type 1 Diabetes Mellitus | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889505) |
| September 29, 2026 | NCT07845955 | JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1D | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | T1DM - Type 1 Diabetes Mellitus | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845955) |
| July 13, 2026 | NCT07699380 | METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D) | University of Washington | Phase 2 | Recruiting | Type 1 Diabetes (T1D), Metabolic Diseases, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07699380) |
| July 6, 2026 | NCT07683026 | Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | Not yet recruiting | Type 1 Diabetes (T1D) | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683026) |
| June 1, 2026 | NCT07616206 | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems | vTv Therapeutics | Phase 2 | Recruiting | Type 1 Diabetes (T1D) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616206) |
| May 29, 2026 | NCT07614412 | SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. | Ministry of Health, Saudi Arabia | Phase 2 | Not yet recruiting | Type 1 Diabetes Mellitus | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614412) |
| May 18, 2026 | NCT07594145 | Precision T1D Platform - New Therapies for Cardio-Renal Complications | Oregon Health and Science University | Phase 2 | Not yet recruiting | Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594145) |
| February 24, 2026 | NCT07430332 | GLP-1 RA for Stage 1 Type 1 Diabetes | Children's Hospital Medical Center, Cincinnati | Phase 2 | Not yet recruiting | Stage 1 Diabetes Mellitus, Type 1 | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07430332) |
| February 19, 2026 | NCT07421518 | Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors | AdventHealth Translational Research Institute | Phase 2 | Not yet recruiting | Type 1 Diabetes, Type 2 Diabetes | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421518) |
| January 8, 2026 | NCT07325201 | Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring. | HealthPartners Institute | Phase 2 | Not yet recruiting | Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07325201) |
| November 25, 2025 | NCT07247734 | The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation | Sponsor not shown (see the record) | Phase 2 | Recruiting | Type 1 Diabetes, Chronic Inflammation, Insulin Sensitivity | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07247734) |
| November 6, 2025 | NCT07225465 | Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin | St Vincent's Hospital Melbourne | Phase 2 | Not yet recruiting | Type 1 Diabetes Mellitus | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225465) |
| November 4, 2025 | NCT07224321 | INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | Mannkind Corporation | Phase 2 | Recruiting | Type 1 Diabetes Mellitus | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224321) |
| October 14, 2025 | NCT07216391 | Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | Recruiting | Type 1 Diabetes Mellitus | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07216391) |
| September 23, 2025 | NCT07187531 | SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | SAb Biotherapeutics, Inc. | Phase 2 | Recruiting | Type 1 Diabetes | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07187531) |
| September 22, 2025 | NCT07186660 | Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes | University of Virginia | Phase 2 | Recruiting | Type 1 Diabetes (T1D), Glycemic Control for Diabetes Mellitus, Insulin, Ketones, Cardiovascular Health | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07186660) |
| August 26, 2025 | NCT07142252 | Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | Recruiting | Type 1 Diabetes Mellitus | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07142252) |
| July 24, 2025 | NCT07083882 | Faecal Autologous Capsule Transplantation for Type 1 Diabetes Mellitus | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 | Recruiting | Type 1 Diabetes Mellitis, Type 1 Diabetes (T1D), Fecal Microbiota Therapy (FMT) | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07083882) |
| June 27, 2025 | NCT07041268 | Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of Rituximab | Pirogov Russian National Research Medical University | Phase 2 | Recruiting | Diabetes Mellitus, Type 1 | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07041268) |
| May 20, 2025 | NCT06981234 | Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial | University of California, San Diego | Phase 2 | Recruiting | Type 1 Diabetes | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06981234) |
| May 16, 2025 | NCT06976619 | The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes | Mayo Clinic | Phase 2 | Recruiting | Type 1 Diabetes, Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06976619) |
| May 9, 2025 | NCT06964087 | Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus | Op-T LLC | Phase 2 | Recruiting | Type I Diabetes | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06964087) |
| February 11, 2025 | NCT06820281 | Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes | Victor Chang Cardiac Research Institute | Phase 2 | Recruiting | Type 1 Diabetes Mellitus | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06820281) |
| February 6, 2025 | NCT06810726 | Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar... | Estar Medical dba Medical Technologies, LTD | Phase 2 | Recruiting | Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer, Chronic Wound... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06810726) |
| November 14, 2024 | NCT06688331 | Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody | PolTREG S.A. | Phase 2 | Recruiting | Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1 | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06688331) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 3 |
| University of Washington | 2 |
| AdventHealth Translational Research Institute | 2 |
| vTv Therapeutics | 1 |
| University Medical Center Groningen | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Pharmasaga Co. Ltd. | 1 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Pirogov Russian National Research Medical University | 1 |
| University of Virginia | 1 |
| University of Florida | 1 |
| University of California, San Diego | 1 |
| PolTREG S.A. | 1 |
| Ministry of Health, Saudi Arabia | 1 |
| HealthPartners Institute | 1 |
| University of Chicago | 1 |
| Victor Chang Cardiac Research Institute | 1 |
| [Mannkind Corporation](https://specstream.ai/data/clinical-trials/company/mannkind-corporation) | 1 |
| University of Alberta | 1 |
| University of Dundee | 1 |
| SAb Biotherapeutics, Inc. | 1 |
| Medical University of Lodz | 1 |
| Op-T LLC | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Mayo Clinic | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 23 |
| Denmark | 4 |
| Canada | 3 |
| Poland | 3 |
| Australia | 3 |
| United Kingdom | 3 |
| Finland | 2 |
| France | 2 |
| Netherlands | 2 |
| Russia | 1 |
| China | 1 |
| Saudi Arabia | 1 |
| Austria | 1 |
| Belgium | 1 |
| Germany | 1 |
| Italy | 1 |
| Lithuania | 1 |
| New Zealand | 1 |
| Slovenia | 1 |
| Spain | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Polish restaurants in the United States](https://specstream.ai/data/businesses/polish-restaurants/united-states)
- [Backflow companies in the United States](https://specstream.ai/data/businesses/backflow-companies/united-states)
- [Hydro jetting companies in the United States](https://specstream.ai/data/businesses/hydro-jetting-companies/united-states)
- [Stock brokers in the United States](https://specstream.ai/data/businesses/stock-brokers/united-states)
- [Cosmetic dentistry practices in the United States](https://specstream.ai/data/businesses/cosmetic-dentistry-practices/united-states)
- [Mortgage lenders in the United States](https://specstream.ai/data/businesses/mortgage-lenders/united-states)
